Diretrizes brasileiras para o manejo da agitação psicomotora: tranquilização rápida 2 – combinações e grupos especiais
DOI:
https://doi.org/10.25118/2763-9037.2021.v11.14Palavras-chave:
Agitação psicomotora, agressividade, agentes tranquilizantes, emergência, transtornos mentaisResumo
Neste último artigo, faremos a comparação entre os diferentes grupos medicamentosos. Posteriormente, apresentaremos as possíveis combinações de medicações para a tranquilização rápida. Por fim, abordaremos o manejo de grupos especiais em agitação psicomotora.
Downloads
Métricas
Referências
International Society of Substance use Professionals (ISSUP). Saúde mental e considerações psicossociais durante o surto de COVID-19 [Internet]. 2020 Apr 3 [cited 2020 Dec 8]. www.issup.net/pt-br/knowledgeshare/publications/2020-04/saude-mentalconsideracoes-psicossociais-durante-surto-covid
Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull. 2020;46:752-7. DOI: https://doi.org/10.1093/schbul/sbaa051
Morgan VA, Waterreus A, Carr V, Castle D, Cohen M, Harvey C, et al. Responding to challenges for people with psychotic illness: updated evidence from the survey of high impact psychosis. Aust N Z J Psychiatry 2017;51:124-40. DOI: https://doi.org/10.1177/0004867416679738
Saxena S, Major M. Physical health of people with severe mental disorders: leave no one behind. World Psychiatry. 2017;16:1-2. 5.Saraceno B, Levav I, Kohn R. The public mental health significance of research on socio-economic factors in schizophrenia and major depression. World Psychiatry. 2005;4:181-5. DOI: https://doi.org/10.1002/wps.20403
Green MF, Horan WP, Lee J, McCleery A, Reddy LF, Wynn JK. Social disconnection in schizophrenia and the general community. Schizophr Bull. 2018;44:242-9. DOI: https://doi.org/10.1093/schbul/sbx082
Thornicroft G, Brohan E, Rose D, Norman Sartorius, Morven Leese, INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional surveyl. Lancet. 2009;373:408-15. DOI: https://doi.org/10.1016/S0140-6736(08)61817-6
Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611-27. DOI: https://doi.org/10.1016/S2215-0366(20)30203-0
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22. DOI: https://doi.org/10.1016/j.bbi.2020.03.031
British Geriatrics Society. Coronavirus: Managing delirium in confirmed and suspected cases [Internet]. 2020 Mar 19 [cited 2020 Dec 7]. www.bgs.org.uk/resources/coronavirus-managingdelirium-in-confirmed-and-suspected-cases
Cui LB, Wang XH, Wang HN. Challenges of facing coronavirus disease 2019: Psychiatric services for patients with mental disorders. Psychiatry Clin Neurosci. 2020;74:371-2. DOI: https://doi.org/10.1111/pcn.13003
Baldacara L, Ismael F, Leite V, Pereira LA, Dos Santos RM, Gomes Júnior VP, et al. Brazilian guidelines for the management of psychomotor agitation. Part 1. Non-pharmacological approach. Braz J Psychiatry. 2019;41:153-67. DOI: https://doi.org/10.1590/1516-4446-2018-0163
Organização Pan-Americana da Saúde (OPAS). Prevenção e controle de infecções durante os cuidados de saúde quando suspeita-se de infecção por novo coronavírus (nCoV) [Internet]. 2020 Mar 3 [cited 2020 Dec 8]. iris.paho.org/handle/10665.2/51910
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683-90. DOI: https://doi.org/10.1001/jamaneurol.2020.1127
Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268-70. DOI: https://doi.org/10.1056/NEJMc2008597
O’Hanlon S, Inouye SK. Delirium: a missing piece in the COVID-19 pandemic puzzle. Age Ageing. 2020;49:497-8. DOI: https://doi.org/10.1093/ageing/afaa094
Garriga M, Pacchiarotti I, Kasper S, Zeller SL, Allen MH, Vázquez G, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17:86-128. DOI: https://doi.org/10.3109/15622975.2015.1132007
World Health Organization. Mental health and psychosocial considerations during the COVID-19 outbreak. Geneva: WHO; 2020.
Richmond JS, Berlin JS, Fishkind AB, Holloman GH Jr, Zeller SL, Wilson MP, et al. Verbal De-escalationof the agitated patient: consensus statement of the American Association for emergency psychiatry project BETA De-escalation workgroup. West J Emerg Med. 2012;13:17-25. DOI: https://doi.org/10.5811/westjem.2011.9.6864
Baldacara L, Diaz AP, Leite V, Pereira LA, Dos Santos RM, Gomes Júnior VP, et al. Brazilian guidelines for the management of psychomotor agitation. Part 2. Pharmacological approach. Braz J Psychiatry. 2019;41:324-35. DOI: https://doi.org/10.1590/1516-4446-2018-0177
Shulman M, Njoku IJ, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013;104:175-84.
Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142:184-6. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.047430
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MC, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995-2002. DOI: https://doi.org/10.1111/jth.14888
Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148-50. DOI: https://doi.org/10.1016/j.thromres.2020.04.041
Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;95:1213-21. DOI: https://doi.org/10.1016/j.mayocp.2020.03.024
Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A, et al. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, doubleblind, parallel-group trial. Int Clin Psychopharmacol. 2015;30:142-50. DOI: https://doi.org/10.1097/YIC.0000000000000064
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria permite que o (s) autor (es) mantenha(m) seus direitos autorais sem restrições. Atribuição-NãoComercial 4.0 Internacional (CC BY-NC 4.0) - Debates em Psiquiatria é regida pela licença CC-BY-NC